西格列汀治疗初诊断2型糖尿病的临床疗效与安全性分析

目的：通过临床研究探讨口服降糖药西格列汀治疗初诊断2型糖尿病的临床疗效及其安全性。方法：收集31例初诊断并未给予药物治疗的2型糖尿病患者,口服DPP-4抑制剂西格列汀治疗12周。观察患者治疗前后空腹血糖（FPG）、餐后2h血糖（2h PG）、全血糖化血红蛋白（Hb A1c）、血压、血常规、肝肾功能、血脂及体重变化,并记录服药后是否出现低血糖、体重增加等不良反应。结果：经西格列汀治疗后,较治疗前显著降低了FPG（P〈0.05）、2h PG（P〈0.01）、Hb A1c（P〈0.05）,患者体重和体质指数（BMI）均有所降低,但无显著性差异（P〉0.05）;而患者血压、肝肾功能、血脂、血红蛋白、白细胞无明显变化。用药期间均能耐受治疗,无严重低血糖事件发生。结论：西格列汀可有效地降低初诊断2型糖尿病患者的血糖水平,并可降低体重,具有良好的安全性。

Clinical efficacy and safety of sitagliptin in the treatment of newly diagnosed type 2 diabetes

Objective： Through clinical studies to explore the clinical efficacy and safety of sitagliptin in the treatment of newly diagnosed type 2 diabetes. Methods： 31 newly diagnosed type 2 diabetes patients who did not take drugs treatment, added to DPP-4 inhibitors sitagliptin for 12 weeks, then check fasting plasma glucose（FPG）,2h postprandial blood glucose（2hPG）, glycosylated hemoglobin（HbAtc）, blood pressure, liver and kidney function, blood lipids and body weight and BMI changes before and after treatment in patients, and record adverse reactions as hypoglycemia and weight gain after taking sitagliptin. Results： After treatment with sitagliptin, compared with pretreatment FPG（P〈0.05）, 2hPG（P〈0.01）, HbA1c（P〈0.05）significantly reduced, the patients＇ body weight was lower but had no significantly difference（P〉0.05）; Blood pressure, liver and kidney function, blood lipids, hemoglobin, white blood cells have no significant changed. During the treatment patients could well tolerate treatment and had no severe hypoglycemic events. Conclusion： Sitagliptin effectively reduced the newly diagnosed type 2 diabetes patients＇ blood glucose level with poor glycemic control, and may play a role in weight reduction, and safety.